Billionaire Stan Druckenmiller’s 10 Stock Picks with Huge Upside Potential

9. Ascendis Pharma A/S (NASDAQ:ASND)

Duquesne Capital’s Stake Value: $24.7 million

Analyst Upside as of June 15: 29.20%

Number of Hedge Fund Holders: 52

Ascendis Pharma A/S (NASDAQ:ASND) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Oppenheimer maintained its Outperform rating on Ascendis Pharma A/S (NASDAQ:ASND) while increasing its price target from $215 to $224 on June 13.

The change comes after a commissioned survey of 20 endocrinologists in the United States who treat hypoparathyroidism showed a high initial demand for the company’s drug, Yorvipath. According to doctors, 20–30% of their hypoparathyroid patients are expected to be taking the medication within a year.

According to the poll, 90% of physicians would recommend Yorvipath to maintain kidney function before renal impairment develops. This affinity is consistent with the prevalence of renal impairment among patients with hypoparathyroidism.

The primary barriers to adoption, according to the majority of physicians, are access and reimbursement; however, Oppenheimer indicated that these worries “may be more anticipation than reality.” Yorvipath’s first full quarter in the United States was described by the firm as “just the beginning of a launch that will outpace expectations.”

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops and distributes novel treatments for unmet medical needs, especially in the fields of oncology and endocrinology.